Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPA | P23025 | 15/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | APEX1 | P27695 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.59 |
| ▸ | GALK1 | P51570 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19644209 | 1.00 | XPA (1.00) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL19644210 | 1.00 | XPA (1.00) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL19644257 | 0.94 | XPA (0.89) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL19644256 | 0.94 | XPA (0.89) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL19644482 | 0.92 | XPA (1.00) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL19644481 | 0.92 | XPA (1.00) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL19644528 | 0.92 | XPA (1.00) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL19654559 | 0.92 | XPA (0.85) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL29388794 | 0.92 | XPA (0.85) | XPAEP300MEN1APEX1KMT2A | |
| SCHEMBL20840294 | 0.91 | XPA (0.83) | XPAEP300MEN1APEX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089577-A1 | KU INHIBITORS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3463371-B1 | KU INHIBITORS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11207296-B2 | XPA inhibitor compounds and their use | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200308154-A1 | KU INHIBITORS AND THEIR USE | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-10-01 | — | — | US | disclosed |
| US-20200222367-A1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-07-16 | — | — | US | disclosed |
| EP-3463371-A1 | KU INHIBITORS AND THEIR USE | Indiana University Research & Technology Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017205503-A1 | KU INHIBITORS AND THEIR USE | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089577-A1 | KU INHIBITORS AND THEIR USE | ZFR, XRCC6, ZFX | XPA 66/4885EP300 771/4885MEN1 2172/4885 |
| US-20200222367-A1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | XPOT, XPA, ERCC4 | XPA 2/4885EP300 1218/4885MEN1 884/4885 |
| US-11207296-B2 | XPA inhibitor compounds and their use | XPOT, XPA, ERCC4 | XPA 2/4885EP300 1218/4885MEN1 884/4885 |
| US-20200308154-A1 | KU INHIBITORS AND THEIR USE | ZFR, XRCC6, ZFX | XPA 66/4885EP300 771/4885MEN1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.